Clinical trial
Fremanezumab, Migraine and Sleep
NCT04693533 is registered in ClinicalTrials.gov with Beth Israel Deaconess Medical Center as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Fremanezumab, Migraine and Sleep
- Lead sponsor
- Beth Israel Deaconess Medical Center
- Phase
- Phase 4
- Overall status
- Terminated
- Start date
- July 29, 2021
- Completion date
- April 1, 2024
- Enrollment
- 22 (actual)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.
migraine disorders, sleep disorder